Trump gives drug makers two years to move to U.S.
A forced relocation timeline would shift pharmaceutical manufacturing capacity toward the U.S. and away from current hubs.
Source →The trace
How it reaches your house.
Starting from Psychiatric Drug Active Pharmaceutical Ingredients, we walked the supply graph hop by hop to the goods you buy and the companies you own. Each step is the engine’s reasoning, scored for confidence and cited where a source backs it.
First impact
Psychiatric Drug Active Pharmaceutical Ingredients →Prices riseAntidepressants and mental health medications
This is a critical upstream input for psychiatric medicines, and the tariff shock raises API costs in a way that the source says can drive higher prices and shortages for depression-related drugs.
94% confidencePsychiatric Drug Active Pharmaceutical Ingredients →Prices easeIndia supplies 55% of this input stream, so a tariff that pushes production back to the U.S. should displace a large share of Indian export sales.
88% confidencePsychiatric Drug Active Pharmaceutical Ingredients →Prices easeChina still accounts for a substantial share of this API supply, so the tariff should reduce its competitive access to the U.S. market.
Hop 2
India →DelaysPalvella Therapeutics, Inc.PVLA
Palvella says its rapamycin API is currently sourced from suppliers in India, so a tariff-driven push to move drug manufacturing out of India is likely to lengthen supplier requalification and logistics lead times.
87% confidenceAntidepressants and mental health medications →Prices risePsychiatric Drug Active Pharmaceutical Ingredients
Antidepressants and mental health medications are highly dependent on APIs, so a forced onshoring timeline should raise near-term sourcing costs and requalification friction for that input.
84% confidenceAntidepressants and mental health medications →DelaysKey Starting Material (KSM) Synthesis
Hop 3
Pharmaceutical Key Starting Materials (KSMs) →Shortage riskAntidepressants and mental health medications
Pharmaceutical KSMs are a critical 95%-weighted input to this medication class, so a tariff-driven reshoring shock should quickly make downstream supply scarcer during the transition.
95% confidencePharmaceutical Key Starting Materials (KSMs) →Shortage riskChina supplies 60% of KSMs, so a forced shift away from current hubs hits the dominant source hardest.
84% confidencePharmaceutical Key Starting Materials (KSMs) →Shortage riskHop 4
Akeso, Inc. →DelaysSummit discloses it relies on third parties, including Akeso, to manufacture its product candidate, so a forced manufacturing relocation for Akeso would most likely stretch lead times for Summit.
66% confidence